Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Nebraska Medical Center
Since being elected to the Lymphoma Research Foundation’s (LRF) Scientific Advisory Board (SAB) in 2001, Dr. Julie Vose, the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology Section in the Department of Internal Medicine at the University of Nebraska Medical Center (UNMC), has taken an active role in the Foundation’s leadership. Along with new SAB member Ranjana Advani, MD, Dr. Vose has formed a new LRF consortium focusing on T-cell lymphoma, which develops from abnormal T-lymphocytes. The group plans to hold meetings to discuss standards of care, conduct clinical trials and potentially award grants and hold workshops in the future assuming fundraising efforts are successful.
“LRF has witnessed great success with its Mantle Cell Lymphoma Consortium, so the T-cell consortium is hoping to have similar impact in identifying new potential targets for therapies and having interactive multidisciplinary research grants funded by the LRF,” she said.
Dr. Vose has also contributed to countless other LRF programs and publications. She has served as an expert consultant for LRF’s Chicago Lymphoma Rounds program for the past two years. In this role, she reviews and approves case study presentations for Continuing Medical Education credits at the events which draw leading lymphoma experts from across the Greater Chicago area. She is a frequent member of the speaking faculty for the national Lymphoma Workshop program and co-chaired the North American Educational Forum on Lymphoma in 2008. In 2009, she was a speaker for LRF’s teleconference “Update on Lymphoma Treatment Options from the 2009 American Society of Hematology (ASH) Annual Meeting” and she has served as a contributor and an editor for the Foundation’s numerous patient resources, including disease-specific booklets and fact sheets.
As a medical student at the University of Nebraska Medical School, Dr. Vose, curious about new discoveries and treatments in the field of lymphoma, pursued her research interests with distinguished researcher, James Armitage, MD. She is proud of the fact that based on findings from this research, “we are able to modify treatments to be more specific for subtypes of lymphomas.” After medical school, Dr. Vose completed both her residency and fellowship at UNMC.
Driven by the exhilaration of new discoveries and enhancements in therapies, Dr. Vose now focuses her research on novel therapies for different subtypes of lymphomas. As for what she finds most exciting in modern lymphoma research, Dr. Vose said, “gene expression and [Single Nucleotide Polymorphism] work that is going on in individual lymphomas, which may direct patients’ individualized therapy in the future.”
Dr. Vose has played a significant role in moving several novel agent lymphoma treatments from Phase I to Phase II and Phase III clinical trials. She recently completed a Phase III trial in the Blood and Marrow Transplant Clinical Trials Network on the Bexxar/BEAM protocol, which focused on the addition of radiolabeled antibodies to high dose chemotherapy and autologous stem cell transplantation.
Her research has led her to be an advisor and member of several advisory boards. Most recently, the American Society of Clinical Oncology (ASCO) elected Dr. Vose to the Undesignated Specialty seat on its Board of Directors. Her 3-year term started in June and she is the only lymphoma specialist on the 20-member board.
When asked for the most important piece of advice she would give to a newly diagnosed lymphoma patient, Dr. Vose said “to conduct plenty of research and to make sure to be treated by a lymphoma specialist.”
Posted: Lymphoma Research Foundation News